COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02899130
Recruitment Status : Unknown
Verified December 2017 by Composite Interceptive Med Science.
Recruitment status was:  Recruiting
First Posted : September 14, 2016
Last Update Posted : December 6, 2017
Information provided by (Responsible Party):
Composite Interceptive Med Science

Brief Summary:
This trial will study the effect of a polyherbal capsule in lowering the viral load of patients with chronic Hepatitis B infection and record the incidence of from Hepatitis B surface antigen elimination in 12 months

Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Drug: Polyherbal Drug: Placebo Not Applicable

Detailed Description:
A placebo controlled randomised trial. 3 herbs that have proven effect on eliminating the virus and normalizing liver function will be given. Equally matched placebo (blinded) will be given randomly to patients. All parameters of hepatitis B infection will be compared between the randomized groups

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Antiviral Effect of 3 Herbs in Chronic Inactive Carriers of Hepatitis B Virus. - A Randomized Placebo Controlled Clinical Trial
Study Start Date : October 2016
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Polyherbal
Combination of 3 whole herbs in a capsule
Drug: Polyherbal
Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
Other Name: Liver Kidney Care

Placebo Comparator: Matching placebo
Similar looking inert capsules
Drug: Placebo
Inactive compound that is similar looking as the intervention

Primary Outcome Measures :
  1. Number of patients with change in mean Hepatitis B Virus (HBV) DNA by at least 2log10 units from baseline at end of treatment for those with HBV DNA ≥ 1000 IU/ml. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Number of patients with change in hepatitis B surface antigen titers from baseline for those with HBV DNA <1000 IU/ml [ Time Frame: 12 months ]
  2. Number of patients with Incidence of seroconversion from Hepatitis B surface antigen to anti-Hepatitis B surface antibody [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults aged above 18 years of age, with inactive chronic hepatitis B (HB) or immune tolerant phase, with or without dyslipidaemia and having all of the following

    1. HBsAg +ve for >6 months and anti-HBs negative
    2. Alanine amino transferase ≤ 2 upper limit of normal
    3. HBeAg positive or negative irrespective of viral DNA load
    4. Not currently on antiviral therapy for Chronic hepatitis B

Exclusion Criteria:

  • Any one of the following

    1. Patients with decompensated liver disease of any etiology(characterized by elevated bilirubin, raised International normalized ratio, or a history of ascites, variceal hemorrhage,hepatic encephalopathy, Spontaneous bacterial peritonitis, hepatorenal syndrome or Hepatocellular carcinoma)
    2. Family history of hepatocellular carcinoma
    3. Patients with HIV and Hepatitis C virus co-morbidity
    4. Pregnant, attempting to conceive, or lactating women
    5. Patients with diabetes mellitus
    6. Recent history of acute coronary syndrome (<6months) or chronic coronary artery disease with poor left ventricular function (by physician / cardiology opinion)
    7. Patients with renal failure ( Creatinine clearance less than 60 ml/min)
    8. Active substance or alcohol abuse and concurrent use of corticosteroids or immunosuppressive agents.
    9. Presence of extra hepatic manifestations
    10. Previously treated with pegylated interferon within the last 2 years
    11. Positive fibroscan or ultrasound elastography showing evidence of fibrosis (F3 and above)
    12. Current or former employees of organic India
    13. Participating in another clinical trial with an active intervention or drug or device with last dose taken within 60 days.
    14. Refusing consent or physician uncomfortable with patient compliance to treatments or follow up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02899130

Layout table for location contacts
Contact: Alben Sigamani, MD +91 8884431444
Contact: Sanjaya Chauhan, Pharm.D +91 9611252350 ext 2388

Layout table for location information
Mazumdar Shaw Mutispeciality Hospital Recruiting
Bangalore, Karnataka, India, 560099
Principal Investigator: Alben Sigamani, MD         
Sponsors and Collaborators
Composite Interceptive Med Science
Layout table for investigator information
Principal Investigator: Alben Sigamani, MD Narayana Hrudayalaya Hospital
Layout table for additonal information
Responsible Party: Composite Interceptive Med Science Identifier: NCT02899130    
Other Study ID Numbers: OI- 002- 2016
First Posted: September 14, 2016    Key Record Dates
Last Update Posted: December 6, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Hepatitis, Chronic